Curis has successfully used this technology and product development strategy to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, hair growth regulation, and cardiovascular disease. Curis is developing product candidates in several important medical fields where there is substantial unmet therapeutic need. These product development initiatives either utilize internal Curis resources or have been partnered with pharmaceutical firms that bring additional resources and expertise to those programs. These product development programs derive primarily from Curis' substantial intellectual property in developmental biology signaling pathways.

Sitting on the Scientific Board, Brigid Hogan, Ph.D. from the Department of Cell Biology at Duke University Medical School. Dr. Hogan is considered a world leader in developmental biology and stem cell research. She is a member of the Institute of Medicine of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and a fellow of the Royal Society of London, among other prestigious groups. She was the scientific co-chair of the 1994 National Institutes of Health report on human embryo research. More recently, she has been named chair of the Department of Cell Biology at Duke University Medical Center (DUMC). She is the first woman to be appointed chair of a basic science department at DUMC. She previously served as director of the Stem Cell and Organogenesis Program at Vanderbilt University Medical Center in Nashville.